| Id: | acc0269 |
| Group: | 1sens |
| Protein: | MET |
| Gene Symbol: | MET |
| Protein Id: | P08581 |
| Protein Name: | MET_HUMAN |
| PTM: | phosphorylation |
| Site: | Tyr1235 |
| Site Sequence: | ARDMYDKEYYSVHNKTGAKLP |
| Disease Category: | Cancer |
| Disease: | Ovarian Cancer |
| Disease Subtype: | MET amp |
| Disease Cellline: | 58As9 |
| Disease Info: | |
| Drug: | crizotinib |
| Drug Info: | "Crizotinib is an oral multi-target tyrosine kinase inhibitor that primarily inhibits ALK and ROS1 kinase activity, used for treating ALK-positive or ROS1-positive non-small cell lung cancer (NSCLC). " |
| Effect: | modulate |
| Effect Info: | The drug induces apoptosis and inhibits AKT and ERK phosphorylation in gastric cancer with MET amplification positivity. |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 22729845 |
| Sentence Index: | 22729845_3 |
| Sentence: | "Inhibition of MET signaling by crizotinib or RNA interference-mediated MET depletion resulted in induction of apoptosis accompanied by inhibition of AKT and extracellular signal-regulated kinase phosphorylation in gastric cancer cells with MET amplification but not in those without it, suggesting that MET signaling is essential for the survival of MET amplification-positive cells." |
Sequence & Structure:
MKAPAVLAPGILVLLFTLVQRSNGECKEALAKSEMNVNMKYQLPNFTAETPIQNVILHEHHIFLGATNYIYVLNEEDLQKVAEYKTGPVLEHPDCFPCQDCSSKANLSGGVWKDNINMALVVDTYYDDQLISCGSVNRGTCQRHVFPHNHTADIQSEVHCIFSPQIEEPSQCPDCVVSALGAKVLSSVKDRFINFFVGNTINSSYFPDHPLHSISVRRLKETKDGFMFLTDQSYIDVLPEFRDSYPIKYVHAFESNNFIYFLTVQRETLDAQTFHTRIIRFCSINSGLHSYMEMPLECILTEKRKKRSTKKEVFNILQAAYVSKPGAQLARQIGASLNDDILFGVFAQSKPDSAEPMDRSAMCAFPIKYVNDFFNKIVNKNNVRCLQHFYGPNHEHCFNRTLLRNSSGCEARRDEYRTEFTTALQRVDLFMGQFSEVLLTSISTFIKGDLTIANLGTSEGRFMQVVVSRSGPSTPHVNFLLDSHPVSPEVIVEHTLNQNGYTLVITGKKITKIPLNGLGCRHFQSCSQCLSAPPFVQCGWCHDKCVRSEECLSGTWTQQICLPAIYKVFPNSAPLEGGTRLTICGWDFGFRRNNKFDLKKTRVLLGNESCTLTLSESTMNTLKCTVGPAMNKHFNMSIIISNGHGTTQYSTFSYVDPVITSISPKYGPMAGGTLLTLTGNYLNSGNSRHISIGGKTCTLKSVSNSILECYTPAQTISTEFAVKLKIDLANRETSIFSYREDPIVYEIHPTKSFISGGSTITGVGKNLNSVSVPRMVINVHEAGRNFTVACQHRSNSEIICCTTPSLQQLNLQLPLKTKAFFMLDGILSKYFDLIYVHNPVFKPFEKPVMISMGNENVLEIKGNDIDPEAVKGEVLKVGNKSCENIHLHSEAVLCTVPNDLLKLNSELNIEWKQAISSTVLGKVIVQPDQNFTGLIAGVVSISTALLLLLGFFLWLKKRKQIKDLGSELVRYDARVHTPHLDRLVSARSVSPTTEMVSNESVDYRATFPEDQFPNSSQNGSCRQVQYPLTDMSPILTSGDSDISSPLLQNTVHIDLSALNPELVQAVQHVVIGPSSLIVHFNEVIGRGHFGCVYHGTLLDNDGKKIHCAVKSLNRITDIGEVSQFLTEGIIMKDFSHPNVLSLLGICLRSEGSPLVVLPYMKHGDLRNFIRNETHNPTVKDLIGFGLQVAKGMKYLASKKFVHRDLAARNCMLDEKFTVKVADFGLARDMYDKEYYSVHNKTGAKLPVKWMALESLQTQKFTTKSDVWSFGVLLWELMTRGAPPYPDVNTFDITVYLLQGRRLLQPEYCPDPLYEVMLKCWHPKAEMRPSFSELVSRISAIFSTFIGEHYVHVNATYVNVKCVAPYPSLLSSEDNADDEVDTRPASFWETS
Select PDB:
| Target | Drug name | MOA | Phase | Status | Disease | Source |
|---|---|---|---|---|---|---|
| MET | CABOZANTINIB S-MALATE | Hepatocyte growth factor receptor inhibitor | 4 | - | hepatocellular carcinoma | EMA |
| MET | CRIZOTINIB | Hepatocyte growth factor receptor inhibitor | 4 | - | diffuse large B-cell lymphoma | DailyMed |
| MET | CABOZANTINIB | Hepatocyte growth factor receptor inhibitor | 4 | - | neoplasm | ATC |
| MET | AMIVANTAMAB | Hepatocyte growth factor receptor inhibitor | 4 | - | neoplasm | ATC |
| MET | CAPMATINIB | Hepatocyte growth factor receptor inhibitor | 4 | - | neoplasm | ATC |
| MET | TEPOTINIB | Hepatocyte growth factor receptor inhibitor | 4 | - | neoplasm | ATC |
| MET | CRIZOTINIB | Hepatocyte growth factor receptor inhibitor | 4 | - | neoplasm | ATC |
| MET | CABOZANTINIB S-MALATE | Hepatocyte growth factor receptor inhibitor | 4 | - | renal cell carcinoma | EMA DailyMed |
| MET | CABOZANTINIB S-MALATE | Hepatocyte growth factor receptor inhibitor | 4 | - | thyroid carcinoma | DailyMed |
| MET | CAPMATINIB HYDROCHLORIDE | Hepatocyte growth factor receptor inhibitor | 4 | - | non-small cell lung carcinoma | EMA FDA DailyMed |
| MET | CRIZOTINIB | Hepatocyte growth factor receptor inhibitor | 4 | - | non-small cell lung carcinoma | EMA DailyMed |
| MET | CRIZOTINIB | Hepatocyte growth factor receptor inhibitor | 4 | Terminated | non-small cell lung carcinoma | ClinicalTrials |
| MET | CRIZOTINIB | Hepatocyte growth factor receptor inhibitor | 4 | Active, not recruiting | non-small cell lung carcinoma | ClinicalTrials |
| MET | AMIVANTAMAB | Hepatocyte growth factor receptor inhibitor | 4 | - | non-small cell lung carcinoma | EMA FDA |
| MET | TEPOTINIB HYDROCHLORIDE | Hepatocyte growth factor receptor inhibitor | 4 | - | non-small cell lung carcinoma | EMA FDA DailyMed |
| MET | TIVANTINIB | Hepatocyte growth factor receptor inhibitor | 3 | Completed | hepatocellular carcinoma | ClinicalTrials |
| MET | CABOZANTINIB | Hepatocyte growth factor receptor inhibitor | 3 | Active, not recruiting | hepatocellular carcinoma | ClinicalTrials |
| MET | CABOZANTINIB | Hepatocyte growth factor receptor inhibitor | 3 | Completed | hepatocellular carcinoma | ClinicalTrials |
| MET | CRIZOTINIB | Hepatocyte growth factor receptor inhibitor | 3 | Completed | carcinoma | ClinicalTrials |
| MET | CRIZOTINIB | Hepatocyte growth factor receptor inhibitor | 3 | Recruiting | lung adenocarcinoma | ClinicalTrials |
| MET | CRIZOTINIB | Hepatocyte growth factor receptor inhibitor | 3 | Recruiting | neoplasm | ClinicalTrials |
| MET | ONARTUZUMAB | Hepatocyte growth factor receptor antagonist | 3 | Completed | neoplasm | ClinicalTrials |
| MET | CABOZANTINIB | Hepatocyte growth factor receptor inhibitor | 3 | Active, not recruiting | renal cell carcinoma | ClinicalTrials ClinicalTrials ClinicalTrials ClinicalTrials |
| MET | CABOZANTINIB | Hepatocyte growth factor receptor inhibitor | 3 | Terminated | renal cell carcinoma | ClinicalTrials |
| MET | SAVOLITINIB | Hepatocyte growth factor receptor inhibitor | 3 | Active, not recruiting | renal cell carcinoma | ClinicalTrials |
Note: Only show clinically investigational or approved drugs with protein targets.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACNo intensity data of this site,
show all other sites!
| MET-Ser1000 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.707 | ||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | 0.707 | ||||
| PDAC | |||||
| UCEC | |||||
| MET-Ser1016 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.707 | ||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | -0.707 | ||||
| MET-Ser1020 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.152 | ||||
| HGSC | |||||
| ccRCC | |||||
| GBM | -1.442 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | 0.826 | ||||
| PDAC | |||||
| UCEC | 0.464 | ||||
| MET-Ser966 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -1.386 | ||||
| GBM | |||||
| HNSC | |||||
| LUAD | 0.137 | ||||
| LUSC | 1.277 | ||||
| non_ccRCC | -0.477 | ||||
| PDAC | |||||
| UCEC | 0.449 | ||||
| MET-Ser988 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.564 | ||||
| GBM | 1.155 | ||||
| HNSC | |||||
| LUAD | -0.59 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| MET-Ser990 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.465 | ||||
| HGSC | |||||
| ccRCC | 1.03 | ||||
| GBM | 0.869 | ||||
| HNSC | |||||
| LUAD | -0.033 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | -1.402 | ||||
| MET-Thr977 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.072 | ||||
| HGSC | 2.004 | ||||
| ccRCC | -0.437 | ||||
| GBM | -1.729 | ||||
| HNSC | |||||
| LUAD | 0.108 | ||||
| LUSC | 0.363 | ||||
| non_ccRCC | -0.729 | ||||
| PDAC | 0.221 | ||||
| UCEC | 0.271 | ||||
| METAP2-Ser49 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.344 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | 0.141 | ||||
| GBM | -1.576 | ||||
| HNSC | 0.748 | ||||
| LUAD | 1.077 | ||||
| LUSC | -0.171 | ||||
| non_ccRCC | -1.523 | ||||
| PDAC | 1.13 | ||||
| UCEC | -0.171 | ||||
| METAP2-Ser60 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.054 | ||||
| HGSC | |||||
| ccRCC | 0.85 | ||||
| GBM | -2.125 | ||||
| HNSC | 0.594 | ||||
| LUAD | 0.509 | ||||
| LUSC | 0.165 | ||||
| non_ccRCC | -0.771 | ||||
| PDAC | |||||
| UCEC | 0.724 | ||||
| METAP2-Ser63 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.958 | ||||
| COAD | -0.811 | ||||
| HGSC | |||||
| ccRCC | 0.753 | ||||
| GBM | -1.801 | ||||
| HNSC | 0.367 | ||||
| LUAD | 0.972 | ||||
| LUSC | -0.06 | ||||
| non_ccRCC | -1.043 | ||||
| PDAC | |||||
| UCEC | 0.665 | ||||
| METAP2-Ser74 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | 0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | -0.707 | ||||
| METTL1-Ser128 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.707 | ||||
| GBM | |||||
| HNSC | 0.707 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| METTL1-Ser27 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.842 | ||||
| GBM | |||||
| HNSC | 1.105 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | -0.264 | ||||
| UCEC | |||||
| METTL13-Ser13 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | 0.707 | ||||
| LUSC | -0.707 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| METTL13-Ser181 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | 0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | -0.707 | ||||
| METTL13-Ser267 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | -0.707 | ||||
| LUSC | 0.707 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| METTL14-Ser27 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | 0.707 | ||||
| LUSC | -0.707 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| METTL14-Ser54 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | 0.707 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | -0.707 | ||||
| METTL14-Thr72 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.707 | ||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | -0.707 | ||||
| METTL16-Ser297 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | 0.707 | ||||
| HNSC | |||||
| LUAD | |||||
| LUSC | -0.707 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| METTL16-Ser329 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | -0.09 | ||||
| HGSC | 1.214 | ||||
| ccRCC | 0.062 | ||||
| GBM | 0.188 | ||||
| HNSC | -2.058 | ||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | 0.264 | ||||
| UCEC | 0.42 | ||||
| METTL16-Ser416 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 1.415 | ||||
| HGSC | |||||
| ccRCC | -0.325 | ||||
| GBM | |||||
| HNSC | -0.932 | ||||
| LUAD | -0.158 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| METTL16-Ser419 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.641 | ||||
| COAD | -0.381 | ||||
| HGSC | 0.167 | ||||
| ccRCC | 0.215 | ||||
| GBM | -1.327 | ||||
| HNSC | -0.966 | ||||
| LUAD | 1.256 | ||||
| LUSC | |||||
| non_ccRCC | 1.758 | ||||
| PDAC | |||||
| UCEC | -0.081 | ||||
| METTL16-Ser450 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | -0.707 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | 0.707 | ||||
| METTL16-Ser453 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.222 | ||||
| HGSC | -2.225 | ||||
| ccRCC | 0.528 | ||||
| GBM | 0.598 | ||||
| HNSC | 0.053 | ||||
| LUAD | 0.301 | ||||
| LUSC | 0.522 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| METTL16-Ser455 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.692 | ||||
| COAD | 0.069 | ||||
| HGSC | -2.841 | ||||
| ccRCC | 0.555 | ||||
| GBM | 0.128 | ||||
| HNSC | -0.142 | ||||
| LUAD | -0.081 | ||||
| LUSC | 0.098 | ||||
| non_ccRCC | 0.105 | ||||
| PDAC | 0.524 | ||||
| UCEC | 0.894 | ||||
| METTL16-Ser498 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | 0.707 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | -0.707 | ||||
| METTL22-Ser132 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 1.599 | ||||
| COAD | |||||
| HGSC | 1.558 | ||||
| ccRCC | -0.904 | ||||
| GBM | |||||
| HNSC | 0.031 | ||||
| LUAD | -0.035 | ||||
| LUSC | -1.091 | ||||
| non_ccRCC | -0.827 | ||||
| PDAC | 0.2 | ||||
| UCEC | -0.531 | ||||
| METTL22-Ser40 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.847 | ||||
| COAD | |||||
| HGSC | 0.214 | ||||
| ccRCC | -0.778 | ||||
| GBM | |||||
| HNSC | 1.621 | ||||
| LUAD | 0.129 | ||||
| LUSC | 0.107 | ||||
| non_ccRCC | -1.657 | ||||
| PDAC | |||||
| UCEC | -0.482 | ||||
| METTL3-Ser17 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | |||||
| ccRCC | -0.707 | ||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | 0.707 | ||||
| METTL3-Ser219 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 1.733 | ||||
| COAD | 0.141 | ||||
| HGSC | -0.789 | ||||
| ccRCC | -0.584 | ||||
| GBM | 0.319 | ||||
| HNSC | 0.611 | ||||
| LUAD | -0.14 | ||||
| LUSC | 0.202 | ||||
| non_ccRCC | -2.27 | ||||
| PDAC | 0.5 | ||||
| UCEC | 0.278 | ||||
| METTL3-Ser243 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -1.475 | ||||
| COAD | -0.326 | ||||
| HGSC | |||||
| ccRCC | 0.147 | ||||
| GBM | |||||
| HNSC | 1.385 | ||||
| LUAD | 0.461 | ||||
| LUSC | 0.784 | ||||
| non_ccRCC | -0.974 | ||||
| PDAC | |||||
| UCEC | |||||
| METTL3-Ser30 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | 0.13 | ||||
| COAD | -0.83 | ||||
| HGSC | 1.402 | ||||
| ccRCC | -0.714 | ||||
| GBM | -0.08 | ||||
| HNSC | 2.042 | ||||
| LUAD | -1.189 | ||||
| LUSC | -0.104 | ||||
| non_ccRCC | -0.364 | ||||
| PDAC | |||||
| UCEC | -0.292 | ||||
| METTL3-Ser350 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | |||||
| HGSC | -1.603 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | 0.418 | ||||
| LUAD | -0.053 | ||||
| LUSC | 1.113 | ||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | 0.125 | ||||
| METTL3-Ser43 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | -0.531 | ||||
| COAD | -0.461 | ||||
| HGSC | 0.778 | ||||
| ccRCC | |||||
| GBM | -0.377 | ||||
| HNSC | -0.223 | ||||
| LUAD | -0.043 | ||||
| LUSC | -0.953 | ||||
| non_ccRCC | 1.531 | ||||
| PDAC | 1.626 | ||||
| UCEC | -1.346 | ||||
| METTL3-Ser50 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.65 | ||||
| HGSC | 0.502 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | -1.152 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| METTL3-Ser64 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.707 | ||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | -0.707 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| METTL3-Thr45 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.707 | ||||
| HGSC | -0.707 | ||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | |||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| METTL3-Thr65 | |||||
|---|---|---|---|---|---|
| Cancer | Intensity | ||||
| BRCA | |||||
| COAD | 0.707 | ||||
| HGSC | |||||
| ccRCC | |||||
| GBM | |||||
| HNSC | |||||
| LUAD | -0.707 | ||||
| LUSC | |||||
| non_ccRCC | |||||
| PDAC | |||||
| UCEC | |||||
| METTL7A-Ser69 | |
|---|---|
| Cancer | Intensity |
| BRCA | |
| COAD | |
| HGSC | 1.47 |
| ccRCC | -0.318 |
| GBM | -0.385 |
| HNSC | |
| LUAD | -0.767 |
| LUSC | |
| non_ccRCC | |
| PDAC | |
| UCEC | |
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| Y | 1235 | P | Lung cancer/carcinoma | Phosphorylation | 23973484 |
| Y | 1235 | U | Prostate cancer | Phosphorylation | 33705609 |
| Y | 1235 | U | Bladder cancer | Phosphorylation | 17062641 |
| Y | 1235 | U | Hepatocellular carcinoma/hepatocarcinoma/hepatoma | Phosphorylation | 21455220 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
